Completing E2B(R3) Compliance in Total Safety 7
|
|
- Branden Newton
- 6 years ago
- Views:
Transcription
1 @ris global Let s Innovate for Life 2016 Completing E2B(R3) Compliance in Total Safety 7 Author: Christian Schmitz-Moormann, Senior Director, Leading Practices Mark Loudon Senior Director, Risk Management Products & Compliance
2 EUROPE USA E2B COMPLIANCE JAPAN Introduction In nearly all industries and markets, companies are subject to increasing regulation concerning transactions, transparency, and privacy and have to bear the costs associated with ensuring compliance to these regulations. In the life sciences industry, this cost is further compounded by the need to monitor potential safety risks related to the use of their products. Regardless of geographic location or organization size, all manufacturers of devices or pharmaceuticals have the regulatory and ethical requirement of collecting, investigating, and monitoring suspected adverse reactions and all associated product use and complaint information. Exchange of such information between stakeholders in electronic format is becoming the standard. The ICH E2B(R2) standard has been implemented and widely used since it was first adopted in The ICH E2B EWG revised the guideline, joined forces with other international standards organizations (such as HL7 and ISO), and the E2B(R3) guideline was finalized in July The shift from E2B(R2) to E2B(R3) is one of the most important regulatory and procedural shifts in the industry, touching the way drug safety and regulatory departments, clinical and licensing partners do business, and requiring significant technological changes. While this is perceived as an evolution rather than a revolution, the challenges in complying with E2B(R3) requirements successfully should not be underestimated. However, due to our industry-leading experience in safety, ArisGlobal has evolved our software products in Safety and other areas to enable companies to implement E2B(R3) on time and on budget and in ways that match real-world, rather than theoretical use. Because of the iterative approach of ICH, and the fact that agencies are even now evolving their final guidances, this paper provides information which was not available when we released our white paper Preparing for E2B(R3): Understanding the Challenges, Options and Opportunities and provides information on how to operationalize and how to go live with E2B(R3). 2
3 Current Status What is available in the current system? The current version of ArisGlobal's Total Safety suite (TS7.2) supports both export and import capabilities of R3 cases through ESM as per the ICH E2B(R3) Implementation Guide released on 12 April 2013 (ICH Step 4 Document) along withpmda local regulations released in Sep Further local regulations will be implemented as they become available during Step 5. Documents While the global requirements were made official in 2013 reaching ICH Step 4 in July, there was a minor revision in November 2014 and a Q&A document was released in November of Regional and local implementation guidelines already exist, or are in the process of being made available. These regional and local implementation guidelines extend the regulatory framework and business rules to be implemented. Frequently, the different regional guides implement divergent rules. The nature of the underlying technical standard for E2B(R3) facilitates this divergence a good thing from the perspective of flexibility, but a bad thing from the perspective of solidifying and aligning regional requirements with each other. It has been made clear that information in the ICH Q&A document supersedes information in the ICH implementation guideline and that the regional/local implementation guidelines again supersede the information in the Q&A document. All current implementations of E2B(R3) are technically independent of IDMP however, some regions (such as Europe) have linked their implementation timetables for these two standards either in whole or in part. The regions have provided guidance as follows: Japan issued a first set of local regulations in September 2013, a second set in October 2014, and a third set in February The EU provided an ICSR Implementation Guide in Dec The US provided a FDA Regional Technical Specifications for ICH E2B(R3) Implementation document which is limited to the Post market submission of Individual Case Safety Reports (ICSRs) for vaccines. This document is still in draft stage (0.3) and dates from May As of this writing, no other regional content is available from the US which goes beyond what is stated in the ICH documents. Other countries have not made official any plans for supporting E2B(R3). However, this does not mean that there are no such plans. Both Canada and Switzerland, for example, are known to work on alignment of their regulatory frameworks with the US and the EU, respectively. 1 In ICH, Step 4 represents the final global document and formally, the standard is therefore finalized from the ICH perspective. However, during the ICH Step 5 (implementation), each agency issues local guidance that can significantly alter how implementation needs to be done for each jurisdiction. 3
4 April 2016 Japan accepts electronic submission in R3 April 2019 R3 submissions mandatory in Japan July 2016 Readiness to accept electronic submission in R3 in EU August 2015 R3 submissions mandatory in US for vaccines (postmarketing) Mid 2017 EU accepts electronic submissions in R3 Japan will start accepting electronic submissions in R3 format on 01-Apr-2016; electronic submission in R3 format will be mandatory in Japan on 01-Apr The PMDA has stated that the authority will not send cases in R3 format before the mandatory date. While for the EU the official date for E2B(R3) readiness is still 01-Jul-2016, this is now interpreted as be able to test with EMA. Production use of E2B(R3) is currently communicated as being planned for mid-2017 ( 6 months post announcement of successful EudraVigilance Audit by the NCAs ). By this date the EMA also plans to send cases out in R3 format. No date has been given yet when electronic submission in E2B(R3) will be mandatory in the EU. The current statement is Post ISO IDMP Implementation which in turn will only start after EU has started accepting R3 format messages. In the US electronic reporting is now mandatory, with the special aspect that for post-marketing information regarding vaccines, E2B(R3) format is required for submission to the authority. If the electronic submitter tool provided by CBER is not used, waivers can be obtained, if a plan for implementation of E2B(R3) reporting for post-marketing cases for vaccines is provided. Beyond this, there are currently no clear rules as to when E2B(R3) reporting will be possible or mandatory in the US. Plan 1 Plan 2 Plan 3 The TS service pack is planned for 31-Aug-2016 release is planned for 31-Jul 2016 ArisGlobal will continue to support changing regulations in accordance with our release policy for the duration of d evelopment s u p p o r t. I n practice, this means that, while support may first be available in upcoming main releases, for regulations that existed when a release was published, and which are modified subsequently, continued compliance will be provided through our service packs 4
5 Here is a tentative overview with regard to E2B(R3) support in the 7.2 and higher releases of the Total Safety Suite: Feature Release in Backport to PMDA business rules evaers Local data entry for R3 (Narrative) 2014 and 2105 local regulations regarding R3 reporting to PMDA R3 submissions through OST Regional R3 Submission validations - FDA Regional R3 regulations and field changes - FDA Regional R3 submission validations - EMA Regional R3 regulations and field changes - EMA Regional R3 submission validations - Japan PMDA report form changes R3 elements in IRT forms emdr3 import emdr3 export Currently, the release is planned for 31-Jul Currently, the TS service pack is planned for 31-Aug Accommodation of additional changes to regulations regarding E2B(R3) will be planned as new information becomes available. PMDA Submission in R3 Format as per ICH Guideline ArisGlobal has been successfully participating in Japan's PMDA Pilot Tests -- in the PMDA Pilot Test of Q2-Q3 2014, ARISj-generated R3 XML files were verified as being compliant with ICH E2B(R3) guideline and the Japanese local regulation of Sep The PMDA Pilot Test of Q2-Q3 2015, which verifies functionality of importing and exporting R3 XML files from ARISj in accordance with ICH E2B(R3) guideline and Japanese local regulation of Feb 2015 is currently ongoing. Items that show up during this test process and require a correction will be addressed in the upcoming TS 7.2 service packs, and at the very latest in TS. 5
6 Pre 7 Releases Backward Forward Compatibility Integration For customers on releases which do not natively support E2B(R3) (releases prior to TS 7), two options will be made available. ArisGlobal will provide access to a hosted environment to which E2B(R3) files can be sent for conversion to R2. The system will also provide acknowledgments to be returned upon successful import of the converted data into the database system. An alternative is to integrate with the ICH or EMA BFC tool, which provides capabilities to convert E2B (R3) to E2B(R2) and vice versa, including acknowledgment messages. Automated integration with the ArisGlobal hosted conversion solution will require some changes to the existing 6.5.x Total Safety systems. Integration with the ICH or EMA BFC tool would require additional steps before and after import. An integration project would have to be agreed. Integration for the ArisGlobal hosted conversion solution is planned as follows: Proposal for integration of BFC Converter for TS 6.5.x Arrival in Receiver Environment Test Wellformedness of XML independent of format Well-Formed XML YES Identify XML R3? YES agconvert R3 to R2 NO NO Converted Data Depends on available DTDs and XSDs (Configuration) Archive Import MDN Returned? NO Attach R2 XML in DMO Attach R3 XML in DMO Nack Returned? NO Import The plan is to provide this integration in a TS 6.5 convergence release (6.5.4) initially by end of Q Attach R2 XML in DMO END 6
7 Conclusion ArisGlobal solutions are fundamentally ready for ICH E2B(R3), and will keep pace with regulatory changes during and after the implementation period. Total Safety 7.2 onwards are inherently ICH E2B(R3) compliant. For versions prior to Total Safety 7, ArisGlobal offers approaches to provide the ability to receive incoming ICH E2B(R3) files, in compliance with the first round of regulatory requirements in Europe. For full two-way exchange of ICH E2B(R3) files, customers will need to upgrade to a then current version of Total Safety 7. For questions about the approach that is right for your company, please contact you client partner 7
8 CORPORATE HEADQUARTERS ArisGlobal, 401 East Las Olas, Suite 1400 Fort Lauderdale, Florida Tel: Fax: REGIONAL OFFICES AMERICA East Coast Office: ArisGlobal LLC 600 College Road East Suite 3100 Princeton, New Jersey Tel: MidWest Office ArisGlobal LLC 377 Butterfield road Suite 260, Lombard IL Tel: Germany ArisGlobal GmbH Inselkammerstrasse Unterhaching, Germany Tel: Italy ArisGlobal GmbH Via Castelfidardo, Roma, Italy Tel: +39 (06) EUROPE Ireland ArisGlobal Ltd. 16a Lincoln Place, Dublin 2 Ireland Tel: Belgium ArisGlobal BVBA Groote Steenweg 323 B-2600 Berchem Belgium Tel: United Kingdom ArisGlobal UK Limited 5-6 Shenley Pavilions Chalkdell Drive Shenley Wood Milton Keynes MK5 6LB England Tel: +44 (0) ASIA PACIFIC Japan ArisGlobal KK TK Shin-Toshin Bldg., 6F , Nishi-Shinjuku, Shinjuku-ku Tokyo, Japan Tel: India ArisGlobal Software Pvt. Ltd. SKR Towers, # 19/2, 15th Cross JP Nagar 4th Phase, Dollars Colony Bangalore , India Tel: ArisGlobal Mysore Center Belagola Industrial area, K.R.S. Road, Metagalli Mysore , India Tel:
<Insert Picture Here> Some Background and What You Should Know and Do Now to Prepare
1 E2B (R3): Some Background and What You Should Know and Do Now to Prepare The following is intended to outline our general product direction. It is intended for information purposes
More informationFDA Information Day: who should attend. Detailed Update on the Latest Information for ICSR and IDMP. Individual Case Safety Reports
FDA Information Day: Individual Case Safety Reports (ICSR) March 13-14, 2012 Event #12030 March 14-15, 2012 Event #12031 The Kirkland Center at the National Labor College Silver Spring, MD, USA PROGRAM
More informationObservers Takuya Noro MHLW X X X Hideto Yokoi PMDA Advisor X X X Adriana Gamboa INFARMED X X X
Page 1 of 7 GHTF SG2 Meeting Location: INFARMED, Av. do Brasil, 53, 1749-004, LISBOA, PORTUGAL Date: 27-29 February 2008 Attendance: Name Organization Email 27/2 28/2 29/2 Miguel Antunes (MA) INFARMED
More informationWhy do we need an addendum to ICH E6?
Addendum to ICH E6 Hideaki Ui, Ph.D. Inspection Director Office of Non-clinical and Clinical Compliance Pharmaceuticals and Medical Devices Agency, Japan Disclaimer The views and opinions expressed in
More informationInternational trend on medical device regulatory convergence
International trend on medical device regulatory convergence Mari Shirotani, Ph.D. Division Director, Office of International Programs Pharmaceuticals and Medical Devices Agency (PMDA) 1st December, 2017
More informationGuidance for Industry
Guidance for Industry Electronic Submission of Lot Distribution Reports for Biological Products This guidance is for immediate implementation. FDA is issuing this guidance for immediate implementation
More informationRole and Vision of PMDA
Role and Vision of PMDA ~Promoting Global Public Health~ Taisuke Hojo Senior Executive Director Pharmaceutical and Medical Devices Agency (PMDA) 1 st Malaysia-Japan Symposium March 10 th, 2015 Today s
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationRecent Development of ICH GCG
Recent Development of ICH GCG Japan Pharmaceutical Manufactures Association ICH Project Committee Minoru Kubota, Ph.D. October 12, 2006 APEC 2006, Tokyo JAPAN ICH Objectives Identification and elimination
More informationQ Manpower. Employment Outlook Survey New Zealand. A Manpower Research Report
Manpower Q4 6 Employment Outlook Survey New Zealand A Manpower Research Report Manpower Employment Outlook Survey New Zealand Contents Q4/6 New Zealand Employment Outlook 1 Regional Comparisons Sector
More informationManpower Employment Outlook Survey Ireland. A Manpower Research Report
Manpower Q3 27 Employment Outlook Survey Ireland A Manpower Research Report Manpower Employment Outlook Survey Ireland Contents Q3/7 Ireland Employment Outlook 1 Regional Comparisons Sector Comparisons
More informationWork plan for GCP Inspectors Working Group for 2018
22 March 2018 EMA/87812 /2018 Committees and Inspections Chairperson: Ana Rodriguez The activities outlined in the work plan for 2018 have been agreed in view of preparation for the Agency s relocation
More informationProgress Report in 2016
APAC Position Paper Progress Report in 2016 APAC RA-EWG Table of Contents INTRODUCTION 1 PROGRESS REPORT ON FOCUSED TOPIC(S) 3 IPMG (International Pharmaceutical Manufacturers Group) 3 JPMA (Japan Pharmaceutical
More informationEVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY
ICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY 1. Opening Discussions The ICH Steering Committee (SC) meeting was chaired by the FDA. The meeting commenced with the provision of
More informationFrank Fowlie. Office of the Ombudsman. Remarks at Marrakesh Public Forum. June 28, Check against delivery
Frank Fowlie Office of the Ombudsman Remarks at Marrakesh Public Forum June 8, 006 Check against delivery Frank Fowlie 6/8/006 Check against Delivery Wellington Remarks 5:7: AM Mr. Chairman, Vint Cerf,
More informationQ Manpower. Employment Outlook Survey Global. A Manpower Research Report
Manpower Q1 29 Employment Outlook Survey Global A Manpower Research Report Manpower Employment Outlook Survey Global Contents Q1/9 Global Employment Outlook 1 International Comparisons Americas International
More informationEV Reporting process for users: Creating and sending ICSRs using EVWEB part II
EV Reporting process for users: Creating and sending ICSRs using EVWEB part II Training Module EV-M3e An agency of the European Union Content Summary Introduction Nullifications and Amendments Creating
More informationSafeguarding public health. The New PV Legislation. Perspective from a Member State
Safeguarding public health The New PV Legislation Perspective from a Member State Mick Foy Reinforcing patient safety in Europe, Zagreb June 2011 Content Background The new EU PV Package ADR Definition
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationGood Pharmacovigilance Practice. Overview of GVP Modules on ADR, PSURs, Signal Management and Additional Monitoring Mick Foy - MHRA
Good Pharmacovigilance Practice Overview of GVP Modules on ADR, PSURs, Signal Management and Additional Monitoring Mick Foy - MHRA Content ADR Reporting Definition & Increased scope Transition arrangements
More informationQ Manpower. Employment Outlook Survey Global. A Manpower Research Report
Manpower Q4 Employment Outlook Survey Global A Manpower Research Report Manpower Employment Outlook Survey Global Contents Q4/ Global Employment Outlook 1 International Comparisons Americas International
More informationAddendum to ICH E6 (R2)
Addendum to ICH E6 (R2) Stephanie Shapley (US FDA) - Rapporteur Dr. Fergus Sweeney (EMA) - Regulatory Chair Date: December 15, 2015 International Council for Harmonisation of Technical Requirements for
More informationElectronic submission of information on medicinal products in accordance to Article 57(2) requirements: Maintenance submission
Electronic submission of information on medicinal products in accordance to Article 57(2) requirements: Maintenance submission SME workshop: Focus on quality for medicines containing chemical entities
More informationCertification Scheme for a Certificate of Pharmaceutical Product (CPP) IFPMA CPP Network Training Toolkit
Certification Scheme for a Certificate of Pharmaceutical Product (CPP) IFPMA CPP Network Training Toolkit 01 Training package Why is training needed? Training modules CPP overview CPP scenario training
More informationPharmacovigilance assessor. National Institute of Pharmacy and Nutrition (OGYÉI) (Hungary) Senior hospital Pharmacist
Curriculum vitae PERSONAL INFORMATION Gyorgyi Fodor WORK EXPERIENCE September 2011 Present Pharmacovigilance assessor National Institute of Pharmacy and Nutrition (OGYÉI) (Hungary) Benefit/risk assessment,
More informationQuality Risk Management ICH Q9
Quality Risk Management ICH Q9 Executive summary for competent authorities and industry Disclaimer: This presentation includes the author s views on quality risk management theory and practice. The presentation
More informationInformation Brochure Professional Certificate in Pharmacovigilance
Information Brochure Professional Certificate in Pharmacovigilance Catalyst Clinical Services Pvt. Ltd. Unit No. 11, CSC-12, Block D1, Sector-16, Rohini, Delhi - 110089 (India) M: +91 9818356273 Email:
More informationFINAL STATUS DOCUMENT
GHTF/SG2/N68R3: 2005 FINAL STATUS DOCUMENT Global Harmonization Task Force Title: Summary of Current Requirements for Where to Send Adverse Event Reports. Authoring Group: GHTF Study Group 2 Endorsed by:
More information# $ pages In Stock. Report Description
Facial Recognition Market (By Technology Type - 2D Facial Recognition, 3D Facial Recognition and Facial Analytics; By End-use Industry - Government and Utilities; Military; Homeland Security; BFSI; Retail;
More informationGCP Inspection by PMDA
2012 EU GCP Inspectors Working Group Workshop London, 12-14 November 2012 Practical Experience in GCP inspections, non EU/EEA countries GCP Inspection by PMDA Kazuko Natsui Inspector for GCP Inspection,
More informationQ Manpower. Employment Outlook Survey Global. A Manpower Research Report
Manpower Q3 2 Employment Outlook Survey Global A Manpower Research Report Manpower Employment Outlook Survey Global Contents Q3/ Global Employment Outlook 1 International Comparisons Americas International
More informationectd IV: It s Almost As Fun As Super Bowl XLIX DIA eregulatory and Intelligence Annual Conference Disclaimer
ectd IV: It s Almost As Fun As Super Bowl XLIX DIA eregulatory and Intelligence Annual Conference Mark Gray FDA/CBER Senior Project Manager 1 Disclaimer Views expressed in this presentation are those of
More informationJapanese submission/approval processes from programming perspective Ryan Hara, Novartis Pharma AG, Basel, Switzerland
PharmaSUG 2015 - Paper SS02 Japanese submission/approval processes from programming perspective Ryan Hara, Novartis Pharma AG, Basel, Switzerland The opinions expressed in this paper and on the following
More informationDraft EU Guidance on Medication Errors
Draft EU Guidance on Medication Errors Revision after PSQCWG and PRAC consultation PSQCWG meeting Brussels, 11 February 2015 Presented by Dr. Thomas Goedecke Senior Scientific Officer, Regulatory Affairs
More informationPharmacovigilance & Managed Care Pharmacy. Issues for Medication Safety in Korea
Pharmacovigilance and Managed Care Pharmacy Issues for Medication Safety in Korea Hyun Taek Shin, Pharm.D. Professor, College of Pharmacy Sookmyung University & President, Korean Academy of Managed Care
More informationJapanese Investment in CE-SEE and. JETRO s Activities in the CE-SEE
Japanese Investment in CE-SEE and JETRO s Activities in the CE-SEE 29 th January, 2013 Takeshi ITO Director General JETRO Vienna I. Japanese Investment in CE-SEE Japanese business in CE-SEE Characteristics
More informationCurrent status on Adverse Event Reporting in Japan
Current status on Adverse Event Reporting in Japan Iku Mitta Safety Reports Management Division, Office of Safety I PMDA 1 Abbreviation ADR: Adverse Drug Reaction DB: Database EPPV:Early Post-Marketing
More informationManpower Employment Outlook Survey India. A Manpower Research Report
Manpower Q2 2009 Employment Outlook Survey India A Manpower Research Report 2 Manpower Employment Outlook Survey India Contents Q2/09 India Employment Outlook 1 Regional Comparisons Sector Comparisons
More informationManpower Employment Outlook Survey Australia
Manpower Employment Outlook Survey Australia 3 215 Australian Employment Outlook The Manpower Employment Outlook Survey for the third quarter 215 was conducted by interviewing a representative sample of
More informationComputer Validation Initiative Committee Membership Requirements
SOP No. CV-02.03 Supersedes SOP No. CV-02.02 Effective Page 1 of 5 Original Issue 18 February 2002 Retirement Computer Validation Initiative Committee Membership Requirements 1. Significant Change(s) from
More informationScottish Textiles SDI International Priority Plan 17/18 SCOTTISH TEXTILES INTERNATIONAL TARGETS
Scottish Textiles SDI International Priority Plan 17/18 The Scottish textile industry consultation (managed by Textiles Scotland (STLA) & SDI) took place in Dec 2016. Over 50 textile leaders/representatives
More informationQ Manpower. Employment Outlook Survey Global. A Manpower Research Report
Manpower Q3 214 Employment Outlook Survey Global A Manpower Research Report Manpower Employment Outlook Survey Global Contents Q3/14 Global Employment Outlook 1 International Comparisons Americas International
More informationUpdate on FDA-EMA QbD Pilot
Update on FDA-EMA QbD Pilot Presented by: Sharmista Chatterjee, PhD Branch Chief (Acting) Office of Process & Facility Office of Pharmaceutical Quality CDER, FDA Dolores Hernán, PhD Quality Office Specialized
More informationBETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS
A2 BETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS March 2012 A3 BETTER REGULATION OF MEDICINES INITIATIVE (BROMI) FIFTH REPORT ON PROGRESS Chief Executive s foreword In January
More informationesubmission roadmap v2.0: Industry viewpoint
TOPRA Veterinary Medicines Symposium 2017 esubmission roadmap v2.0: Industry viewpoint Patrizia Oelker Boehringer Ingelheim Animal Health ENABLING AND PROMOTING EXCELLENCE IN THE HEALTHCARE REGULATORY
More informationTRAINING CALENDAR 2018
TRAINING CALENDAR 2018 Quality Efficiency Innovation CLINICAL RESEARCH AND COMPLIANCE 9 July Data Integrity Assessment WORKSHOP An effective approach to identify data integrity gaps on some pratical examples
More informationPMDA EPOCH Toward 2020
PMDA International Vision PMDA EPOCH Toward 2020 As one of the world s top three medical products regulatory agencies comparable to its American and European counterparts, PMDA aims to: 1. Secure the highest
More informationDirect Patient ADR reporting system in Japan. Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Direct Patient ADR reporting system in Japan Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan Disclaimer The views and opinions expressed in the following PowerPoint
More informationTHE NATIONAL INVESTMENT IN RESEARCH. Professor Vicki Sara Chair, Australian Research Council
THE NATIONAL INVESTMENT IN RESEARCH Professor Vicki Sara Chair, Australian Research Council National Innovation System Public Research Institutes Knowledge Creativity Flow Private Enterprise Universities
More informationVersion Number: 004 Controlled Document Sponsor: Controlled Document Lead:
Chief Investigators and Principal Investigators in Research Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Policy Governance To set out the responsibilities of
More informationPowering solar in a world full of energy. CONERGY.COM
Powering solar in a world full of energy. CONERGY.COM Contents 4 Editorial 6 Who we are 8 Products & services 10 Project business 12 Quality & engineering 16 Customers 20 References The power of solar
More informationAsia Key Economic and Financial Indicators 16-May-17
Asia Key Economic and Financial Indicators -May-7 ASEAN Brunei (BN) Cambodia (KH) Indonesia () Laos (LA) Malaysia () Myanmar (MM) Philippines () Singapore () Thailand () Vietnam () East Asia China (CN)
More information2015 Annual FDA Medical Device Quality System Data. Inspections, FDA Form 483 Observations, and Warning Letter Citations
2015 Annual FDA Medical Device Quality System Data Inspections, FDA Form 483 Observations, and Warning Letter Citations Why is FDA making these data available? In support of the FDA s Transparency and
More informationUsing Technology to Improve Hand Hygiene Compliance and Patient Outcomes
Using Technology to Improve Hand Hygiene Compliance and Patient Outcomes GOJO SmartLink Hand Hygiene Solutions Did You Know? Healthcare-Associated Infections (HAIs) account for 1.7 million infections annually
More informationCommission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics Oslo
Commission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics 30.1.2017 Oslo 3.2.2017 O. Konttinen 1 Background Based on directive 2001/20/EC of the clinical trials on medicinal
More informationLeadership, Teamwork and Patient Safety
Leadership, Teamwork and Patient Safety ISQua Background Founded in 1985, international office moved from Australia to Dublin in 2008 Non-profit, independent organisation Members from 70 Countries (Individual
More informationEuropean Patients Academy (EUPATI) Update
European Patients Academy (EUPATI) Update EMA meeting with patient/consumer organisations 11 Dec 2013 Maria Mavris EURORDIS // EUPATI WP4 Co-Lead For patient-centric medicines R&D and to contribute to
More informationHow Will Europe s New Medtech Code Affect Your Meetings?
How Will Europe s New Medtech Code Affect Your Meetings? Meet the Presenters Pat Schaumann, CMP, CSEP, DMCP, HMCC Sr. Director of Healthcare Compliance Pat.schaumann@maritz.com Simon Dufaur Head of Strategy
More informationMedDRA User Group. Paris, April 16, 2015 Victoria Newbould, European Medicines Agency. An agency of the European Union
MedDRA User Group Paris, April 16, 2015 Victoria Newbould, European Medicines Agency An agency of the European Union HMA meeting 28 November 2013 HMA agreed with the deliverables to be completed over the
More informationRegulatory Submissions Trends Survey 2002 Ellen Semple Date received (in revised form): 18th March, 2003
Ellen Semple joined CDC Solutions in July 2002 and is VP of Global Marketing. She oversees the strategic direction of CDC Solutions global marketing teams and works directly with CDC s work headquarters
More informationQ Manpower. Employment Outlook Survey Global. A Manpower Research Report
Manpower Q3 211 Employment Outlook Survey Global A Manpower Research Report Manpower Employment Outlook Survey Global Contents Q3/11 Global Employment Outlook 1 International Comparisons Americas International
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Sponsorship SOP-RES-001 Version Number 3 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s) Reviewer(s) Teresa
More informationISO14155: 2011 Clinical investigation of medical devices for human subjects - Good Clinical Practice - ISO TC194 WG4 Madoka Murakami PMDA, Japan
ISO14155: 2011 Clinical investigation of medical devices for human subjects - Good Clinical Practice - ISO TC194 WG4 Madoka Murakami PMDA, Japan What is GCP? Good Clinical Practice (GCP) is an international
More informationBUFFALO S SHIPPING POST Serving Napa Valley Since 1992
BUFFALO S SHIPPING POST Serving Napa Valley Since 1992 2471 Solano Ave Napa, CA 94558 707-226-7942 FAX: 707-226-1510 buffship.com October 21, 2017 RE: New Pricing Hi Everyone, Because of continual fuel
More informationPublic Disclosure Copy. Implementation Status & Results Report Philippines: Extractive Industries Transparency Initiative Implementation (P128290)
Public Disclosure Authorized EAST ASIA AND PACIFIC Philippines Energy & Extractives Global Practice Recipient Executed Activities Technical Assistance Loan FY 2014 Seq No: 1 ARCHIVED on 07-Jul-2015 ISR19833
More informationAdvanced European Regulatory Affairs
Update on the developments in Europe for Regulatory Affairs and the impact on product development and life cycle management Course Language: English 210 Early Bird discount for enrolment by 7th March 2018
More informationHealth Workforce Policies in OECD Countries
Health Workforce Policies in OECD Countries Right Jobs, Right Skills, Right Places Gaetan Lafortune, OECD Health Division EU Joint Action Health Workforce Planning and Forecasting Closure Event, Belgium,
More informationPMDA Update: Its current situation
PMDA Update: Its current situation and future direction Tatsuya Kondo, M.D. Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA), Japan 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam
More informationSTANDARD OPERATING PROCEDURE FOR PHLEBOTOMY ROOM SOPs: Preparing, Maintaining and Training
STANDARD OPERATING PROCEDURE FOR PHLEBOTOMY ROOM SOPs: Preparing, Maintaining and Training SOP Number: Phleb 100.03 Version Number & Date: 3 rd version; 28 Feb 2011 Superseded Version Number & Date (if
More informationTake a Course of Action.
Take a Course of Action. When you choose RAPS Online University, you ll be on track to expand your regulatory knowledge and advance your career. Our comprehensive learning provides an immersive experience
More informationICH Regulators Forum. Dr Peter Arlett EU
Dr Peter Arlett EU International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use In this presentation ICH Regulators Forum: Background ICH Regulators
More informationRiver Use Update Oct by Steve Sullivan
Grand Canyon River Office River Use Update Oct-2014 -by Steve Sullivan Topics Commercial Use Numbers Noncommercial Use (NC) Numbers NC Lottery Applications NC Trip Sizes, Boats, and TAOTs NC Unused Launches
More informationManpower Employment Outlook Survey Australia
Manpower Employment Outlook Survey Australia 3 16 The Manpower Employment Outlook Survey for the third quarter 16 was conducted by interviewing a representative sample of 1,5 employers in Australia. Australian
More informationQ Manpower. Employment Outlook Survey India. A Manpower Research Report
Manpower Q1 2008 Employment Outlook Survey India A Manpower Research Report Manpower Employment Outlook Survey India 2 Manpower Employment Outlook Survey India Contents Q1/08 India Employment Outlook 1
More informationDelivery time frame for the EU portal and EU database
17 December 2015 EMA/760345/2015 Endorsed Draft time frame presented to European Medicines Agency Management Board 01 October 2015 Draft timeframe presented to IT Directors and Member States during the
More informationManpowerGroup Employment Outlook Survey New Zealand
ManpowerGroup Employment Outlook Survey New Zealand 2 18 New Zealand Employment Outlook The ManpowerGroup Employment Outlook Survey for the second quarter 18 was conducted by interviewing a representative
More informationManpowerGroup Employment Outlook Survey India
ManpowerGroup Employment Outlook Survey India 3 17 India Employment Outlook The ManpowerGroup Employment Outlook Survey for the third quarter 17 was conducted by interviewing a representative sample of
More informationCURRICULUM VITAE. 23 December 1968, Varna, Bulgaria
CURRICULUM VITAE NAME: Milen Nikolaev Vrabevski, MD DATE/PLACE OF BIRTH: 23 December 1968, Varna, Bulgaria CONTACT DETAILS: South Side Business Centre 38, Maystor Aleksi Rilets Str., 5th fl. Res. Distr.
More informationNSF Dietary Supplement Complete Service Offering. Experts in supplement auditing, consulting, testing and training.
NSF Dietary Supplement Complete Service Offering Experts in supplement auditing, consulting, testing and training www.nsf.org Dietary Supplement Quality Training NSF Dietary Supplement Quality Training
More informationCorporate. Research Governance Policy. Document Control Summary
Corporate Research Governance Policy Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation Date: Review Date:
More informationManpowerGroup Employment Outlook Survey Global
ManpowerGroup Employment Outlook Survey Global 4 17 Global Employment Outlook ManpowerGroup interviewed over 59, employers across 43 countries and territories to forecast labor market activity in Quarter
More informationManpowerGroup Employment Outlook Survey Global
ManpowerGroup Employment Outlook Survey Global 4 217 ManpowerGroup interviewed over 59, employers across 43 countries and territories to forecast labor market activity in Quarter 4 217. All participants
More informationThe business is on a growth trajectory and central to this growth is the need to attract successful recruitment consultants.
LONDON PRINCIPLE CONSULTANT Our client is a privately owned, fast growing recruitment consultancy. The company is a main player in its market place and has won a number of accolades within its sector.
More informationMETS Ignited Mining Equipment Technology Services
METS Ignited Mining Equipment Technology Services Mining and METS Sector Engagement The sum is greater than the parts Sarah Boucaut General Manager: Education and Leadership Skills March 21 2017 What is
More informationeuropean citizens Initiative
A new right for eu citizens You can set the agenda! guide to the european citizens Initiative European Commission Secretariat-General B-1049 Brussels Manuscript completed in November 2011 Luxembourg: Publications
More informationSTATEMENT. JEFFREY SHUREN, M.D., J.D. Director, Center for Devices and Radiological Health Food and Drug Administration
STATEMENT JEFFREY SHUREN, M.D., J.D. Director, Center for Devices and Radiological Health Food and Drug Administration Institute of Medicine Committee on Patient Safety and Health Information Technology
More informationSOP: New Revised Reviewed Effective Date: 08 October Approved by : Supervisor/Manager Risk/Ethics Sr. Mgmt Committees Board/Councils
Title: Assessment of Study Feasibility Manual: RI MUHC Policies and Procedures Human Research SOPs Originating Dept/ Service: RI MUHC Division of Clinical Research SOP: New Revised Reviewed Effective Date:
More informationThe EUREKA Initiative An Opportunity for Industrial Technology Cooperation between Europe and Japan
EUREKA The EUREKA Initiative An Opportunity for Industrial Technology Cooperation between Europe and Japan Brussels, 12 March 2014 Susanne Madders Senior International Cooperation Advisor EUREKA Secretariat,
More informationCOUNTRY OVERALL COMPARATIVE SIZE
OUR OBJECTIVE TODAY Raise your awareness that there are that are several Brazilian IT services and solutions providers more than capable to fit your bill with great quality, delivery precision and competitive
More informationAssessment of patient, consumer and healthcare professional organisations compliance with EMA eligibility criteria
15 March 2018 EMA/698917/2017 Stakeholders and Communication Division Assessment of patient, consumer and healthcare professional organisations compliance with EMA eligibility criteria 1. Introduction
More informationConsideration on Global Harmonization
ICDRA Workshop I Consideration on Global Harmonization Oct. 25, 2012 Dr. Nobumasa Nakashima Director, Office of International Programs PMDA, Japan 1 Current Harmonization Activities ICH: International
More information...FREEDOM TO EXPLORE YOUR REGULATORY NEEDS
...FREEDOM TO EXPLORE YOUR REGULATORY NEEDS 1 Table of Contents Pg 3 Pg 4 Pg 5 About Ivowen Limited Meet the team Pharmaceutical Regulatory Affairs Services: Human & Veterinary Pg 5 Pg 5 National Procedures
More informationTitle: A Blueprint for Outsourcing Audits of Approved GxP Validations
8 th International Conference and Exhibition on Pharma Audit, GMP, GCP SCIENTIFIC PROGRAM 8:30-9:30 REGISTRATIONS 9:30-10:00 OPENING CEREMONY KEYNOTE FORUM 10:00-10:05 INTRODUCTION Title: A Blueprint for
More informationPresentation to the Federal, Provincial and Territorial (FPT) Deputy Ministers of Health Meeting
Presentation to the Federal, Provincial and Territorial (FPT) Deputy Ministers of Health Meeting Gatineau, Quebec June 10, 2011 (Amended for Project Web Page) Canadian Pharmaceutical Bar Coding Project
More informationLinking Researchers with their Research: Persistent identifiers, registries, and interoperability standards
Linking Researchers with their Research: Persistent identifiers, registries, and interoperability standards 12 November 2013 Rebecca Bryant, PhD Director of Community, ORCID R.Bryant@orcid.org http://orcid.org/0000-0002-2753-3881
More information4th International Medical Expo & Conference
Exhibiting Information 4th International Medical Expo & Conference 2018 Dates: February 21(Wed)- 23 (Fri), 2018 Venue: INTEX Osaka, Japan Organised by: Reed Exhibitions Japan Ltd. Supported by: Union of
More informationDeveloping a regulatory strategy for pharmacy education and training
Council meeting 9 June 2011 Public business Developing a regulatory strategy for pharmacy education and training Purpose To agree the need for a regulatory strategy for pharmacy education and training
More informationEIT Raw Materials Call for KAVA Regional Innovation Scheme and Internationalisation projects Instructions and process description
EIT Raw Materials Call for KAVA Regional Innovation Scheme and Internationalisation projects Instructions and process description March 2016 1. Purpose and scope of this document This document describes
More informationBRIDGING GRANT PROGRAM GUIDELINES 2018
BRIDGING GRANT PROGRAM GUIDELINES 2018 1. Introduction Bridging Grants are a program of assistance that target early stage proof of concept and knowledge transfer, product and services development and
More information